Progenics Pharmaceuticals, Inc. Securities Litigation
On or around 06/11/2020 (Notice of voluntarily dismissal)
Filing Date: November 22, 2019
According to the Complaint, Progenics Pharmaceuticals, Inc. is an oncology company focused on the development and commercialization of targeted medicines and artificial intelligence to find, fight and follow cancer. The Company’s pipeline includes therapeutic agents designed to precisely target cancer and prostate-specific membrane antigen targeted imaging agents for prostate cancer.
This action stems from a proposed transaction announced on October 2, 2019, pursuant to which Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc., will acquire Progenics in an all-stock transaction.
On November 12, 2019, Defendants caused the Form S-4 Registration Statement (the "S-4") to be filed with the SEC in connection with the Proposed Transaction. The S-4 solicits the Company’s shareholders to vote in favor of the Proposed Transaction. The Complaint alleges that the S-4 is materially incomplete and misleading, in violation of Sections 14(a) and 20(a) of the Exchange Act.
This case was voluntarily dismissed on March 5, 2020. A related case continues under Docket 19-CV-21200 in the District of New Jersey. Plaintiff filed an amended Complaint on April 21. On April 24, this case was transferred to the Southern District of New York. On June 11, this case was voluntarily dismissed.
Company & Securities Information
Defendant: Progenics Pharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: PGNX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Martin Johnson, et al. v. Progenics Pharmaceuticals, Inc., et al.
COURT: D. Delaware
DOCKET #: 19-CV-02183
JUDGE: Hon. Maryellen Noreika
DATE FILED: 11/22/2019
CLASS PERIOD START: 10/02/2019
CLASS PERIOD END: 11/22/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Faruqi & Faruqi, LLP (Wilmington 2019)
First Identified Complaint (FIC) Filings:
Class Action Complaint for Violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934
Plaintiff's Notice of Voluntary Dismissal without Prejudice
U.S. District Court Civil Docket
Michael A. Bernstein IRA, et al. v. Progenics Pharmaceuticals, Inc., et al.